Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders.

[1]  A. Saul,et al.  Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines. , 2008, Vaccine.

[2]  Hong Zhou,et al.  In Immunization with Plasmodium falciparum Apical Membrane Antigen 1, the Specificity of Antibodies Depends on the Species Immunized , 2007, Infection and Immunity.

[3]  J. Sattabongkot,et al.  Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer , 2007, Malaria Journal.

[4]  A. Saul,et al.  Enhanced antibody production in mice to the malaria antigen AMA1 by CPG 7909 requires physical association of CpG and antigen. , 2007, Vaccine.

[5]  A. Saul,et al.  Formulation of vaccines containing CpG oligonucleotides and alum. , 2007, Journal of immunological methods.

[6]  Hong Zhou,et al.  Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates. , 2007, Vaccine.

[7]  M. Kieny,et al.  A review of human vaccine research and development: malaria. , 2007, Vaccine.

[8]  T. Richie,et al.  Malaria vaccines: are we getting closer? , 2007, Current opinion in molecular therapeutics.

[9]  Christiana N. Fogg,et al.  Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges , 2007, Vaccine.

[10]  J. Shiloach,et al.  Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25 , 2007, Proceedings of the National Academy of Sciences.

[11]  J. Shiver,et al.  Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex , 2006, Proceedings of the National Academy of Sciences.

[12]  Hong Zhou,et al.  Immunity to Recombinant Plasmodium falciparum Merozoite Surface Protein 1 (MSP1): Protection in Aotus nancymai Monkeys Strongly Correlates with Anti-MSP1 Antibody Titer and In Vitro Parasite-Inhibitory Activity , 2006, Infection and Immunity.

[13]  Hong Zhou,et al.  Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide. , 2006, Vaccine.

[14]  L. Miller,et al.  Overproduction of Pichia pastoris or Plasmodium falciparum protein disulfide isomerase affects expression, folding and O-linked glycosylation of a malaria vaccine candidate expressed in P. pastoris. , 2006, Journal of biotechnology.

[15]  M. Minami,et al.  A CpG-containing oligodeoxynucleotide as an efficient adjuvant counterbalancing the Th1/Th2 immune response in diphtheria-tetanus-pertussis vaccine. , 2005, Vaccine.

[16]  Hong Zhou,et al.  Phase 1 Clinical Trial of Apical Membrane Antigen 1: an Asexual Blood-Stage Vaccine for Plasmodium falciparum Malaria , 2005, Infection and Immunity.

[17]  C. Coban,et al.  Effect of CpG Oligodeoxynucleotides on the Immunogenicity of Pfs25, a Plasmodium falciparum Transmission-Blocking Vaccine Antigen , 2004, Infection and Immunity.

[18]  D. Jackson,et al.  Analysis of Immunological Nonresponsiveness to the 19-Kilodalton Fragment of Merozoite Surface Protein 1 of Plasmodium yoelii: Rescue by Chemical Conjugation to Diphtheria Toxoid (DT) and Enhancement of Immunogenicity by Prior DT Vaccination , 2003, Infection and Immunity.

[19]  A. Saul,et al.  In Vitro Studies with Recombinant Plasmodium falciparum Apical Membrane Antigen 1 (AMA1): Production and Activity of an AMA1 Vaccine and Generation of a Multiallelic Response , 2002, Infection and Immunity.

[20]  D. Kaslow,et al.  Improved Immunogenicity and Efficacy of the Recombinant 19-Kilodalton Merozoite Surface Protein 1 by the Addition of Oligodeoxynucleotide and Aluminum Hydroxide Gel in a Murine Malaria Vaccine Model , 2002, Infection and Immunity.

[21]  R. Anders,et al.  Specificity of the Protective Antibody Response to Apical Membrane Antigen 1 , 2001, Infection and Immunity.

[22]  P. Barr,et al.  Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum , 1994, Infection and immunity.

[23]  S. Cryz,et al.  Effect of carrier selection on immunogenicity of protein conjugate vaccines against Plasmodium falciparum circumsporozoites , 1988, Infection and immunity.

[24]  R. Carter,et al.  The 230-kDa gamete surface protein of Plasmodium falciparum is also a target for transmission-blocking antibodies. , 1987, Journal of immunology.